Evonetix Overview
Pro stress-test →Evonetix is a Cambridge, United Kingdom-based biotechnology company that develops DNA synthesis technology utilizing a specialized electronic silicon chip approach to produce high-fidelity genetic material. The company is developing technology that will put a gene foundry into every lab, giving researchers access to high-quality, gene-length DNA at unprecedented speed and scale.
Strategic Profile
Pro stress-test →The platform uses silicon arrays for DNA synthesis of genes having high GC content, enabled by semiconductor microfabrication which enables various miniaturized reaction sites. CEO Colin McCracken notes the ultimate goal is to provide a desktop synthesiser to all labs for researchers to utilize, with recent installation at Imperial College London representing a significant step forward in delivering on this vision.
Competitive Landscape
Pro stress-test →Key competitors include DNA Script, Quantapore, Bionano Genomics, Pacific BioSciences of California, and Oxford Nanopore Technologies. DNA Script develops enzymatic DNA synthesis, producing the SYNTAX platform benchtop DNA printer for custom DNA oligos, founded in 2014 and based in France. Molecular Assemblies focuses on enzymatic DNA synthesis serving therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology sectors, founded in 2013 in San Diego.
Industry Context
Evonetix operates in DNA synthesis platforms.
Key facts
Founded: 2015 · Headquarters: Cambridge, United Kingdom · Employees: 25 employees · Revenue: $6.4 million (2026) · Market cap: N/A